Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03345173 · ClinicalTrials.gov registry record · Phase 3
Facilitating Rapid Naltrexone Initiation
A Phase 3 study of Opioid Dependence, sponsored by New York State Psychiatric Institute.
- Active
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03345173 is a Phase 3 study of Opioid Dependence that is active but no longer recruiting, run by New York State Psychiatric Institute. The registered enrollment target is 100 participants, below the 155-participant average among 29 other Opioid Dependence trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03345173, a Phase 3 study of Opioid Dependence, is active but no longer recruiting, sponsored by New York State Psychiatric Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The incidence of opioid use disorders (OUDs) has increased to near-epidemic proportions. While maintenance with long-acting opioids such as methadone or buprenorphine represents an effective treatment strategy, it may be unacceptable to many individuals. As a result, long-acting injectable naltrexone (XR-NTX), an antagonist medication that blocks the effects of opioids for at least 4 weeks, is now indicated for relapse prevention following detoxification. This randomized, controlled trial aims to test the efficacy of a glutamate modulator at facilitating a rapid non-opioid based naltrexone induction.
Conditions Studied
Interventions
- DRUG CI-581-a
- DRUG CI-581-b
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-11-25 |
| Est. Completion | 2024-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03345173
The ClinicalTrials.gov registry entry for NCT03345173 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 155-participant average among 29 other Opioid Dependence trials with a reported enrollment target (35% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Dependence appearing as the primary indexed condition, and to 2 interventions - of which CI-581-a is the first listed.
NCT03345173 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03345173 about?
NCT03345173 is a clinical study titled "Facilitating Rapid Naltrexone Initiation". The incidence of opioid use disorders (OUDs) has increased to near-epidemic proportions. While maintenance with long-acting opioids such as methadone or buprenorphine represents an effective treatment strategy, it may be unacceptable to many individuals. As a result, long-acting injectable naltrexon...
What is the current status of trial NCT03345173?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2017-11-25. Estimated completion is 2024-10.
What conditions does trial NCT03345173 study?
This clinical trial studies the following conditions: Opioid Dependence.
What interventions are being tested in trial NCT03345173?
The interventions under investigation include: CI-581-a (DRUG), CI-581-b (DRUG).
Who is sponsoring clinical trial NCT03345173?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03345173 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Buprenorphine Treatment for Opioid Dependence
COMPLETED · Phase 3
-
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
COMPLETED · Phase 3
-
Neuromodulation and Cognitive Training in Opioid Use Disorder
RECRUITING · NA
-
Intervening With Opioid-Dependent MothersMothers and Infants
RECRUITING · NA
-
fMRI and Opioid Abstinence
RECRUITING
-
Better Options for Chronic Cancer Pain
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.